Liufu Deng Selected Research

Immunotherapy

1/2024	TIM-3 inhibitors: a promising strategy for tumor immunotherapy.
1/2024	Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy.
1/2024	Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
12/2023	Noncanonical MAVS signaling restrains dendritic cell-driven antitumor immunity by inhibiting IL-12.
6/2023	Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth.
1/2023	STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells.
12/2022	Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity.
1/2021	Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
1/2020	cGAS-STING-mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy.
8/2010	The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liufu Deng Research Topics

Disease

21	Neoplasms (Cancer) 01/2024 - 08/2010
11	Bites and Stings (Sting) 06/2023 - 11/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 01/2021
2	Inflammation (Inflammations) 10/2021 - 11/2017
1	Thrombosis (Thrombus) 01/2023
1	Sepsis (Septicemia) 01/2023
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Carcinogenesis 01/2014
1	Infections 01/2014
1	Diarrhea 01/2014
1	Obesity 10/2012
1	Thinness 10/2012

Drug/Important Bio-Agent (IBA)

9	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 11/2014
6	Interferon Type IIBA 01/2023 - 11/2014
4	Proteins (Proteins, Gene)FDA Link 12/2023 - 11/2014
4	CytokinesIBA 06/2023 - 06/2013
4	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2023 - 11/2014
3	InterferonsIBA 06/2023 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2024 - 09/2013
2	Mitochondrial DNA (mtDNA)IBA 01/2023 - 01/2017
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2014
2	Therapeutic UsesIBA 01/2018 - 10/2015
1	RNA (Ribonucleic Acid)IBA 12/2023
1	Antiviral Agents (Antivirals)IBA 12/2023
1	Messenger RNA (mRNA)IBA 06/2023
1	NF-kappa B (NF-kB)IBA 06/2023
1	Carbonic Anhydrase InhibitorsIBA 06/2023
1	Peptides (Polypeptides)IBA 01/2023
1	Androgen Receptors (Androgen Receptor)IBA 12/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	Caspase 8 (Caspase-8)IBA 10/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	AntibodiesIBA 01/2021
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2017
1	Blocking AntibodiesIBA 10/2015
1	B7-H1 AntigenIBA 02/2014
1	Interleukin-17 (Interleukin 17)IBA 01/2014
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2014
1	Interleukin-22 (IL-22)IBA 01/2014
1	LigandsIBA 01/2014
1	Lymphotoxin-alpha (Lymphotoxin)IBA 10/2012

Therapy/Procedure

10	Immunotherapy 01/2024 - 08/2010
8	Radiotherapy 01/2024 - 06/2013
5	Therapeutics 01/2020 - 08/2010
1	Chemoradiotherapy 01/2024
1	Drug Therapy (Chemotherapy) 01/2024
1	Ligation 01/2023
1	Punctures 01/2023
1	Castration 12/2022
1	Transplantation 10/2012